Business Wire

Data from Ozanimod Clinical Development Program in Relapsing Forms of Multiple Sclerosis to Be Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Share

Celgene Corporation (NASDAQ:CELG) today announced it will present 13 scientific abstracts, including new analyses from the Phase 3 ozanimod clinical development program in adults with relapsing forms of multiple sclerosis (RMS), at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm, September 11-13, 2019. Ozanimod is an investigational oral, sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5).

“Celgene is committed to furthering our understanding of multiple sclerosis (MS) and the full potential of ozanimod,” said Terrie Curran, President, Global Inflammation and Immunology, Celgene. “We look forward to sharing these new analyses with the MS community, including data on the long-term efficacy and safety of ozanimod in adults with relapsing forms of MS.”

Ozanimod is an investigational compound that is not approved for any use in any country.

Abstracts for presentation include:

New Analyses from the Ozanimod Clinical Development Program

Abstract #P615: Ozanimod efficacy in RMS by baseline thalamic volume quartile: a post hoc exploratory analysis of Phase 3 RADIANCE (Poster Session 1; Wednesday, September 11, 5:15-7:15 p.m. CET; lead author: Jeffrey)

Abstract #P980: Effect of ozanimod on the relationship between changes in cognition and grey matter volume in RMS: a post hoc exploratory analysis of the Phase 3 SUNBEAM trial (Poster Session 2; Thursday, September 12, 5:15-7:15 p.m. CET; lead author: Schippling)

Abstract #P993: Absorption, metabolism, and excretion, in vitro pharmacology, and clinical pharmacokinetics of ozanimod, a novel sphingosine 1-phosphate receptor agonist (Poster Session 2; Thursday, September 12, 5:15-7:15 p.m. CET; lead author: Tran)

Abstract #P996: Effect of ozanimod on circulating leukocyte subtypes: data from a randomized, open-label, Phase 1 study in patients with relapsing multiple sclerosis (Poster Session 2; Thursday, September 12, 5:15-7:15 p.m. CET; lead author: Harris)

Abstract #P1031: Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study (Poster Session 2; Thursday, September 12, 5:15-7:15 p.m. CET; lead author: Steinman)

Abstract #P1047: Effect of ozanimod on neurofilament light chain level in relapsing multiple sclerosis: pooled results from Phase 2 and Phase 3 trials (Poster Session 2; Thursday, September 12, 5:15-7:15 p.m. CET; lead author: Harris)

Cohort Studies of Patients with Multiple Sclerosis in Sweden

Abstract #148: Cardiovascular disease in patients with multiple sclerosis: a nationwide cohort study in Sweden (Oral: Free Communication 2 – Comorbidities; Thursday, September 12, 9:18-9:30 a.m. CET; lead author: Piehl)

Abstract #P761: Risk of osteoporosis and fractures in patients with multiple sclerosis: a nationwide cohort study in Sweden (Poster Session 2; Thursday, September 12, 5:15-7:15 p.m. CET; lead author: Montgomery)

Abstract #P762: Infections in patients with multiple sclerosis: a nationwide cohort study in Sweden (Poster Session 2; Thursday, September 12, 5:15-7:15 p.m. CET; lead author: Montgomery)

Abstract #272: Risk of comorbidity in patients with multiple sclerosis: a nationwide cohort study in Sweden (Oral: Scientific Session 11 – Registry-based MS Research; Friday, September 13, 9:10-9:22 a.m. CET; lead author: Piehl)

Health Economics and Outcomes Research Data

Abstract #P1065: Treatment patterns among treatment-naive multiple sclerosis patients in a commercially insured US population (Poster Session 2; Thursday, September 12, 5:15-7:15 p.m. CET; lead author: Kantor)

Abstract #P1068: Systematic literature review and network meta-analysis of Ozanimod compared with other treatments in relapsing-remitting multiple sclerosis (Poster Session 2; Thursday, September 12, 5:15-7:15 p.m. CET; lead author: Tencer)

Abstract #EP1590: Number-needed-to-treat analysis and risk-benefit assessment of Ozanimod compared with first-line disease-modifying therapies for relapsing-remitting multiple sclerosis (ePoster; lead author: Kumar)

Abstracts can be found on the ECTRIMS website here.

Celgene will also host a satellite symposium, “The Evolution of MS Study Outcomes: Relevance to Clinical Practice Today,” exploring current trends in MS research and care, including the implementation of novel study endpoints in the clinic, magnetic resonance imaging (MRI) assessment of brain volume change and lesions, the use of patient-reported outcomes and cognition assessment to measure disability progression, and real-world data. The symposium will take place on September 11, 2019 from 12:30-1:30 p.m. CET.

A New Drug Application for ozanimod for the treatment of adults with RMS is currently under review by the U.S. Food and Drug Administration (FDA). Under the Prescription Drug User Fee Act, the FDA has set its action date as March 25, 2020. The European Medicines Agency also accepted for review the Marketing Authorization Application for ozanimod for the treatment of adults with relapsing-remitting multiple sclerosis, with a regulatory decision in the European Union expected in the first half of 2020.

About Ozanimod

Ozanimod is an investigational oral, sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). Ozanimod causes lymphocyte retention in lymphoid tissues. The mechanism by which ozanimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve the reduction of lymphocyte migration into the central nervous system.

Ozanimod is in development for immune-inflammatory indications including RMS, ulcerative colitis and Crohn's disease.

About Multiple Sclerosis

Multiple sclerosis (MS) is a disease in which the immune system attacks the protective myelin sheath that covers the nerves. The myelin damage disrupts communication between the brain and the rest of the body. Ultimately, the nerves themselves may deteriorate — a process that's currently irreversible. Signs and symptoms vary widely, depending on the amount of damage and the nerves affected. Some people living with MS may lose the ability to walk independently, while others experience long periods of remission during which they develop no new symptoms. MS affects approximately 400,000 people in the U.S. and approximately 2.5 million people worldwide.

RMS is characterized by clearly defined attacks of worsening neurologic function. These attacks — often called relapses, flare-ups or exacerbations — are followed by partial or complete recovery periods (remissions), during which symptoms improve partially or completely with no apparent progression of disease. RMS is the most common disease course at the time of diagnosis. Approximately 85 percent of patients are initially diagnosed with RMS, compared with 10-15 percent with more progressive forms of the disease.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next‐generation solutions in protein homeostasis, immuno‐oncology, epigenetics, immunology and neuro‐inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the U.S. Securities and Exchange Commission, including factors related to the proposed transaction between Bristol-Myers Squibb and Celgene, such as, but not limited to, the risks that: management’s time and attention is diverted on transaction related issues; disruption from the transaction make it more difficult to maintain business, contractual and operational relationships; legal proceedings are instituted against Bristol-Myers Squibb, Celgene or the combined company that could delay or prevent the proposed transaction; and Bristol-Myers Squibb, Celgene or the combined company is unable to retain key personnel.

Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.

All trademarks are the property of their respective owners.

Contact information

Investors:
Nina Goworek
Executive Director, Investor Relations
908-673-9711

Media:
Catherine Cantone
Senior Director, Corporate Communications
908-897-4256

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Velodyne Shows Velarray Lidar in Sleek Car Designs at IAA 2019 Conference14.9.2019 19:39:00 CESTPress release

Velodyne Lidar, Inc. (Hall 8.0, Booth A13) is showcasing the pristine integration of Velarray lidar sensors into consumer vehicles to make currently available, high-end electric vehicles safer at the IAA 2019 Conference. Velodyne has addressed the market need for lidar technology that enables high-level Advanced Driver Assistance Systems (ADAS) for safe navigation and collision avoidance, all within a compact form factor. The lidar is situated behind the vehicle’s windshield for streamlined, flawless integration. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190914005023/en/ Can you see the lidar? The Velarray is embedded in a sleek electric car at IAA 2019 (Hall 8.0, Booth A13). (Photo: Velodyne Lidar) Velodyne booth visitors can see how the Velodyne Velarray™ sensors are beautifully integrated into sleek, high-end vehicles, maintaining their aerodynamic design. The Velarray’s small, embeddable form factor is a powerful so

Insurance Leaders and Visa Digitize Claims Payouts for Individuals and Businesses When They Need It Most13.9.2019 14:37:00 CESTPress release

Emergencies like car collisions or natural disasters come when people least expect them, leaving individuals unprepared to complete insurance forms, confirm claim estimates, and pay repair shop and medical expenses. During these times, quick access to funds is critical. Visa is committed to working with innovative companies in the insurance industry to help turn outdated and time-consuming processes associated with insurance claim payouts into near real-time1 access to payments when individuals, families and businesses need them the most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190913005323/en/ Visa Direct powers real-time insurance payouts, providing people access to their funds when they need it most. (Graphic: Business Wire) “Visa believes that money shouldn’t be a stressor in moments of crisis and waiting on average six to 10 days to access the money from insurance checks, is outdated, frustrating and costly to th

Wipro Positioned as a Leader in the IDC MarketScape for Utilities Customer Experience, Worldwide13.9.2019 12:55:00 CESTPress release

Wipro Limited (NYSE: WIT) (BSE: 507685) (NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has been positioned as a leader in the IDC MarketScape: Worldwide Professional Services Firms for Utilities Customer Experience 2019 Vendor Assessment (doc #US42713318, July 2019). Wipro has been recognised for key strengths including provider of fast as-a-service implementations of IT systems, for Utilities and cost-effective quality of service delivery models. The study evaluated the Utilities Customer Experience (CX) transformation and digital capabilities of 15 service providers and mapped them based on strategies, capability and market impact related parameters. Key Highlights include- The report notes Wipro’s internal program aimed at comprehensively addressing the challenges faced by utilities. Selected employees are assigned to one of six "domain tribes" — customer services, network operations, new energy servic

Jefferies to Hold Global Relief Day in Support of Hurricane Relief in the Bahamas, Monday, September 1613.9.2019 12:00:00 CESTPress release

Jefferies confirmed that the firm’s global trading day for Hurricane Dorian relief efforts in the Bahamas will be held on Monday, September 16. Jefferies will offer investors around the world the opportunity to join efforts to assist those affected by the devastation of this event by trading with Jefferies. As previously announced, Jefferies will donate all net trading commissions on Monday, September 16, from U.S., European and Asia equity, fixed income and foreign exchange trading. In addition, Jefferies will donate an additional $1 million itself, and all 3,656 employees worldwide will be given the opportunity to personally donate to the relief effort. These contributions will be allocated to a series of charities with the goal of quickly getting funds to relief efforts directly involved in the rescue and recovery efforts. Rich Handler, Chairman and Chief Executive Officer of Jefferies, and Brian Friedman, Chairman of the Executive Committee, commented: "All of us at Jefferies are d

 Knopp Biosciences to Present Data Characterizing Its Kv7 Technology Platform’s Potential for Delivering Precision Medicines to Treat Diverse Neurological and Smooth Muscle Diseases13.9.2019 10:00:00 CESTPress release

Knopp Biosciences LLC today reports data demonstrating that compound subgroups from its proprietary library of potassium-channel modulators selectively target Kv7 channel subtypes associated with a wide range of neurological and smooth muscle diseases. The data is being presented at the International Kv7 Channels Symposium 2019 in Naples, Italy. Presentation Title: The Re-emergence of Kv7 Drug Discovery Presenter: Michael Bozik, M.D., CEO, Knopp Biosciences Date & Time: September 13, 4:35 pm CEST Michael Bozik, M.D., Chief Executive Officer of Knopp, will present the data derived from the Company’s proprietary library of more than 3,000 novel compounds directed to modulating the Kv7 channel, which regulates the flow of potassium ions across cell membranes. The data demonstrate that specific subgroups of Kv7 compounds selectively modulate different Kv7 channel subtypes across ranges of channel activation and inhibition, enabling selection of compounds capable of targeting neurological d

PenSam Selects Moody’s Analytics Economic Scenario Generator to Support New Risk Modeling Framework13.9.2019 09:00:00 CESTPress release

Moody’s Analytics, a global provider of financial intelligence, announced today that its software has been selected by PenSam, one of Denmark’s leading labor market pension and insurance firms. PenSam will be using the Moody’s Analytics Economic Scenario Generator (ESG) for actuarial liability valuations, risk management, strategic asset allocation, and asset and liability management (ALM). The Moody’s Analytics ESG is an award-winning simulation framework which clients deploy in areas such as actuarial reporting, risk and capital calculation and analysis, and investment and ALM analysis. PenSam will also take advantage of the Moody’s Analytics Automation Module, which allows insurers to streamline their modeling processes by automating model set-up, execution, and validation, in turn reducing production time and cost. “The Danish pensions and insurance market is going through a period of change, with insurance companies across the country reassessing their risk management frameworks a